Clinical outcomes of patients with two small hepatocellular carcinomas

doi:10.4254/wjh.v13.i10.1439

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4695)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

196

WORD

161

HTML

1944

Figures (1-2)

346

Tables (1-3)

369

Sum=3016

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

473

Download

1206

Sum=1679

Oct 27, 2021 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Hepatol. Oct 27, 2021; 13(10): 1439-1449
Published online Oct 27, 2021. doi: 10.4254/wjh.v13.i10.1439

Table 1 Baseline characteristics of 104 patients with two hepatocellular carcinomas according to synchronous or sequential tumor

	All (n = 104)	Synchronous group (n = 59)	Sequential group (n = 45)	P value
Age, yr, median (IQR)	63 (10)	63 (10)	63 (9)	0.41
Gender, n (%)				0.08
Male	89 (85.6)	51 (86.4)	38 (84.4)
Female	15 (14.4)	8 (13.6)	7 (15.6)
Aetiology, n (%)				0.73
Alcohol	12 (11.5)	8 (13.6)	4 (8.9)
HCV	42 (40.4)	22 (37.3)	20 (44.4)
HBV	15 (14.4)	8 (13.6)	7 (15.6)
NASH	5 (4.8)	4 (6.8)	1 (2.2)
Alcohol and HCV	18 (17.3)	9 (15.3)	9 (20.0)
Other¹	12 (11.5)	8 (13.6)	4 (8.9)
Cirrhosis status, n (%)				0.07
Non-cirrhotic	10 (9.6)	3 (5.1)	7 (15.6)
Cirrhotic	94 (90.4)	56 (94.9)	38 (84.4)
CTP class, n (%)				0.1
A	66 (63.5)	35 (59.3)	31 (68.9)
B	25 (24.0)	13 (22.0)	12 (26.7)
C	13 (12.5)	11 (18.6)	2 (4.4)
MELD, median (IQR)	9.6 (6)	11 (7)	8 (5)	0.01
AFP (μg/L), median (IQR)	9.6 (24.0)	8.6 (26.0)	10.4 (22.8)	0.61
Combined tumour diameter (cm), median (IQR)	3.5 (1.7)	3.8 (1.7)	3.4 (1.2)	0.28
Transplanted, n (%)	25 (24)	18 (30.5)	7 (15.6)	0.08
Death, n (%)	36 (34.6)	23 (39.0)	13 (28.9)	0.28

¹Other refers to aetiologies not listed here and is inclusive of: Mixed aetiologies, autoimmune hepatitis, hereditary haemochromatosis, α-1-antitrypsin deficiency and cryptogenic liver disease. IQR: Interquartile range; AFP: α-feto protein; CTP: Child-Turcotte-Pugh; HBV: Hepatitis B virus; HCV: Hepatitis C virus; MELD: Model for End-Stage Liver Disease score; NASH: Non-alcoholic steatohepatitis.

Citation: Pham AD, Vaz K, Ardalan ZS, Sinclair M, Apostolov R, Gardner S, Majeed A, Mishra G, Kam NM, Patwala K, Kutaiba N, Arachchi N, Bell S, Dev AT, Lubel JS, Nicoll AJ, Sood S, Kemp W, Roberts SK, Fink M, Testro AG, Angus PW, Gow PJ. Clinical outcomes of patients with two small hepatocellular carcinomas. World J Hepatol 2021; 13(10): 1439-1449
URL: https://www.wjgnet.com/1948-5182/full/v13/i10/1439.htm
DOI: https://dx.doi.org/10.4254/wjh.v13.i10.1439